156 related articles for article (PubMed ID: 14996721)
1. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.
Struckmann K; Schraml P; Simon R; Elmenhorst K; Mirlacher M; Kononen J; Moch H
Cancer Res; 2004 Mar; 64(5):1632-8. PubMed ID: 14996721
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.
Faronato M; Muzzonigro G; Milanese G; Menna C; Bonfigli AR; Catalano A; Procopio A
Histol Histopathol; 2007 Oct; 22(10):1109-18. PubMed ID: 17616938
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of BTG2 suppresses growth, migration, and invasion of human renal carcinoma cells in vitro.
Sima J; Zhang B; Sima XY; Mao YX
Neoplasma; 2016; 63(3):385-93. PubMed ID: 26925784
[TBL] [Abstract][Full Text] [Related]
4. Microarray gene expression profiling and analysis in renal cell carcinoma.
Liou LS; Shi T; Duan ZH; Sadhukhan P; Der SD; Novick AA; Hissong J; Skacel M; Almasan A; DiDonato JA
BMC Urol; 2004 Jun; 4():9. PubMed ID: 15212686
[TBL] [Abstract][Full Text] [Related]
5. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y
J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of the p53-inducible antiproliferative gene BTG2 in hepatocellular carcinoma is associated with overexpression of the cell cycle-related proteins.
Zhang Z; Chen C; Wang G; Yang Z; San J; Zheng J; Li Q; Luo X; Hu Q; Li Z; Wang D
Cell Biochem Biophys; 2011 Sep; 61(1):83-91. PubMed ID: 21327578
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
8. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.
Schraml P; Struckmann K; Bednar R; Fu W; Gasser T; Wilber K; Kononen J; Sauter G; Mihatsch MJ; Moch H
Am J Pathol; 2001 Feb; 158(2):593-601. PubMed ID: 11159196
[TBL] [Abstract][Full Text] [Related]
9. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes.
Amatschek S; Koenig U; Auer H; Steinlein P; Pacher M; Gruenfelder A; Dekan G; Vogl S; Kubista E; Heider KH; Stratowa C; Schreiber M; Sommergruber W
Cancer Res; 2004 Feb; 64(3):844-56. PubMed ID: 14871811
[TBL] [Abstract][Full Text] [Related]
10. FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma.
Kojima T; Shimazui T; Horie R; Hinotsu S; Oikawa T; Kawai K; Suzuki H; Meno K; Akaza H; Uchida K
Genes Chromosomes Cancer; 2010 Apr; 49(4):379-89. PubMed ID: 20095040
[TBL] [Abstract][Full Text] [Related]
11. [Effects of SIPL1 screened by suppression subtractive hybridization (SSH) on biological function and drug resistance of renal cell carcinoma cells].
Li CY; Yao AM; Chang XN; Guo YH; Xu R
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):897-903. PubMed ID: 24506958
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
13. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.
Hwa JS; Kim HJ; Goo BM; Park HJ; Kim CW; Chung KH; Park HC; Chang SH; Kim YW; Kim DR; Cho GJ; Choi WS; Kang KR
Proteomics; 2006 Feb; 6(3):1077-84. PubMed ID: 16372272
[TBL] [Abstract][Full Text] [Related]
14. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of the BTG2 gene in TPA- or RA-treated HL-60 cell lines.
Cho BO; Jeong YW; Kim SH; Park K; Lee JH; Kweon GR; Park JC
Oncol Rep; 2008 Mar; 19(3):633-7. PubMed ID: 18288394
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.
Chen D; Gassenmaier M; Maruschke M; Riesenberg R; Pohla H; Stief CG; Zimmermann W; Buchner A
J Urol; 2014 Feb; 191(2):479-86. PubMed ID: 24012533
[TBL] [Abstract][Full Text] [Related]
17. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
Allory Y; Matsuoka Y; Bazille C; Christensen EI; Ronco P; Debiec H
Clin Cancer Res; 2005 Feb; 11(3):1190-7. PubMed ID: 15709188
[TBL] [Abstract][Full Text] [Related]
18. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
[TBL] [Abstract][Full Text] [Related]
19. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma.
Visapää H; Bui M; Huang Y; Seligson D; Tsai H; Pantuck A; Figlin R; Rao JY; Belldegrun A; Horvath S; Palotie A
Urology; 2003 Apr; 61(4):845-50. PubMed ID: 12670587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
